KRAS and non-small cell lung carcinoma: It was then demonstrated that resistance to ganetespib and to the combined treatment with docetaxel in KRAS mutant NSCLC patients was caused by hyperactivation of ERK1/2-p90RSK-mTOR signaling pathway and by circumventing the G2-M checkpoint arrest of the cell cycle (171, 172).